Atoum Manar Fayiz, Zreig Dalia Abu, Abu Zreig Laith Majed
Faculty of Applied Health Sciences, Medical Laboratory Science, Hashemite University, Zarqa, Jordan.
Faculty of Medicine, Jordan University of Science and Technology, Ar-Ramtha, Jordan.
Infect Disord Drug Targets. 2023;23(1):e180822207640. doi: 10.2174/1871526522666220818124416.
Restoring everyday civil life from the devastating pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be only by the development of an efficient vaccine. As of April 12, 2022, 497,960,492 confirmed cases of COVID-19 were reported, including 6,181,850 lives having been lost worldwide and completely paralyzing the d global economy. Detection of a novel coronavirus SARS-CoV-2 in Wuhan, in December 2019, and the genetic sequence of SARS-CoV-2 that was published on January 11, 2020, leads to a global race, to prepare for a preventive vaccine. No single institution can develop a vaccine individually because there are many stages for developing and producing a successful vaccine. Since this virus threatens the health, the economy, and society the demand for a fast-track vaccine is understandable. This article tries to give an overview of vaccine 'candidates' development and clinical trials, and it mentions some challenges of using these vaccines for managing SARS-CoV-2.
从严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的毁灭性大流行中恢复日常公民生活，只能依靠研发高效疫苗。截至2022年4月12日，全球报告了497960492例新冠肺炎确诊病例，其中6181850人死亡，全球经济完全陷入瘫痪。2019年12月在武汉检测到新型冠状病毒SARS-CoV-2，以及2020年1月11日公布的SARS-CoV-2基因序列，引发了一场全球竞赛，以研发预防性疫苗。没有任何一个机构能够单独研发出疫苗，因为成功研发和生产疫苗有许多阶段。由于这种病毒威胁着健康、经济和社会，对快速研发疫苗的需求是可以理解的。本文试图概述候选疫苗的研发和临床试验情况，并提及使用这些疫苗应对SARS-CoV-2的一些挑战。
